Sign In
Buy FBRX
$76.98
+0.450 (+0.588%)
At Close: Jul 30, 2026
NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,”
Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders
08:00am, Friday, 25'th Aug 2023
NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,”
Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update
04:01pm, Monday, 14'th Aug 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-detailed diseases, today announced second quarter
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
04:01pm, Tuesday, 01'st Aug 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced key R&D updates for FB-102 and the clo
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
04:01pm, Friday, 19'th May 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced the issuance of an equity inducement a
Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update
04:01pm, Monday, 15'th May 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2023 results and provide
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update
04:05pm, Friday, 31'st Mar 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced full year 2022 results and provided a
Mr. David Gryska Appointed to Forte Biosciences Board of Directors
04:05pm, Thursday, 12'th Jan 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors. Mr. Gryska w
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
04:01pm, Monday, 14'th Nov 2022
DALLAS--( BUSINESS WIRE )--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provi
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors
04:01pm, Monday, 14'th Nov 2022
DALLAS--( BUSINESS WIRE )--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors.
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
08:59am, Wednesday, 13'th Jul 2022 Benzinga
Gainers
Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session
04:00pm, Tuesday, 12'th Jul 2022 Benzinga
Gainers
Canoo Inc. (NASDAQ: GOEV) shares jumped 79.9% to $4.2627 after Walmart signed a definitive agreement with the company to purchase 4,500 all-electric delivery vehicles, beginning with the Life
Best Penny Stocks to Buy Today? 3 to Watch on May 3rd
01:33pm, Tuesday, 03'rd May 2022 PennyStocks
What to know about buying penny stocks on May 3rd
The post Best Penny Stocks to Buy Today? 3 to Watch on May 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
BiomX: Undervalued With Multiple Upcoming Catalysts
06:42pm, Wednesday, 06'th Oct 2021
BiomX: Undervalued With Multiple Upcoming Catalysts
Los Angeles, California--(Newsfile Corp. - September 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of
